Skip to main content

Recombinant Human Parkin pS65 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # E3-166

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
E3-166-025

Key Product Details

Source

Sf 21 (baculovirus)

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Spodoptera frugiperda, Sf 21 (baculovirus)-derived human Parkin protein
Met1 - Val465

Purity

>90%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain.

Predicted Molecular Mass

52 kDa

Activity

Reaction conditions will need to be optimized for each specific application. Parkin pS65 has substantial ligase activity in the absence of added activators.  

Formulation, Preparation and Storage

E3-166
Formulation Supplied as a solution in Tris, NaCl, Glycerol, Brij-35 and TCEP.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.

Background: Parkin

The E3 Ubiquitin ligase Parkin (encoded by the PARK2 gene) is an essential part of the cellular machinery that participates in the removal of damaged mitochondria. Mutations in PARK2 are known to cause a form of Parkinson's disease known as autosomal recessive juvenile Parkinson's disease (AR-JP), and the mechanisms by which defective Parkin ligase contributes to the dopaminergic cell death in this disease is an area of intense investigation. Reported substrates for Parkin include BCL2, GPR37, MIRO1, MFN1, MFN2, TOMM20, USP30, and many others. Parkin (an RBR-class Ubiquitin ligase) structures have been reported by multiple groups, and reveal that the ligase is folded upon itself to produce an auto-inhibited state. The auto-inhibition is relieved by interactions with PINK1 kinase (which can phosphorylate both Parkin and Ubiquitin at serine residue number 65) and pS65 phospho-Ubiquitin by mechanisms that are under investigation. In vitro, Parkin may be activated via phosphorylation by PINK1 or addition of low concentrations of pS65-phosphoubiquitin. Parkin has been reported to generate poly-Ubiquitin chains in K6, K11, K48, and K63 linkages both in vitro and in vivo. This recombinant protein is phosphorylated on serine 65.

References

  1. Bingol, B. et al. (2014) Nature 510: 370.
  2. Ordureau, A. et al. (2014) Mol. Cell 56: 360.
  3. Riley, B.E. et al. (2013) Nat. Comm. 4: 1982.
  4. Saraff, S.A. et al. (2013) Nature 496: 372.
  5. Spratt, D.E. et al. (2013) Nat. Comm. 4: 1983.
  6. Trempe, J.F. et al. (2013) Science 340: 1451.
  7. Wauer T. et. al. (2015) Nature 524: 370.
  8. Wauer T. & Komander, D. (2013) EMBO J. 32: 2099.

Long Name

Parkinson Disease [autosomal recessive, juvenile] 2, Parkin [PARK2], transcript variant 1

Alternate Names

AR-JP, PARK2, PDJ, PRKN

Entrez Gene IDs

5071 (Human); 50873 (Mouse); 56816 (Rat)

Gene Symbol

PRKN

UniProt

Additional Parkin Products

Product Documents for Recombinant Human Parkin pS65 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Parkin pS65 Protein, CF

For research use only

Loading...
Loading...
Loading...